Articles On Creso Pharma (ASX:CPH)

The acquisition of Sierra Sage Herbs will propel Creso into the US CBD market, as it pursues further US and international footprints. Cannabidiol (CBD) product sales in the US are already going gangbusters, and a new forecast predicts the m...

Medicinal cannabis company Creso Pharma (CPH) posts a 74 per cent quarter-on-quarter increase in revenue to $2.02 million for the December quarter Contributors include Nova Scotia-based Mernova Medicinal which had a record quarter of sales...

Perth-based medicinal cannabis play Creso Pharma is making its first foray into the metaverse, announcing it has snapped up digital land “strategically located” next to a virtual mansion owned by Snoop Dogg. 

Creso Pharma is about take its first step on the metaverse, buying a plot of digital land on The Sandbox next to a mansion owned by rapper Snoop Dogg. The metaverse is seen as the next big thing, and is expected to become one of the biggest...

Key points ASX cannabis shares could benefit from new COVID-fighting research Cannabidiol (CBD) has proven effective in mice Researchers hope to launch human trials ASX cannabis shares haven’t exactly shot the lights out over the past f...

In December France banned the sale of hemp flower and leaf loaded with CBD, but the Conseil d’Etat provisionally overruled the decision on Wednesday – pending further examination of the order. Basically, the French court said that flowers...

Creso Pharma (ASX: CPH | FRA: 1X8) is set to distribute its range of CBD and hemp animal health anibidiol® products throughout the US, following a deal signed with CERES Natural Remedies.

Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.

Creso Pharma (ASX: CPH) will be the first ASX listed stock to acquire 100% of a psychedelics company. CPH is set to acquire Canada based Halucenex Life Sciences Inc., an established psychedelics company developing treatments for a range of...

Creso Pharma (ASX: CPH) just released its preliminary financial reports for the year, which as expected show a bunch of impairments, debt clean ups and other scary looking one off costs that come with a balance sheet clean up - these are al...

Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfoli...

Once again, medicinal cannabis company Creso Pharma (ASX: CPH) keeps pleasantly surprising us. Today they have REALLY surprised us by announcing they have acquired a Psychedelics company.

Creso Pharma (ASX: CPH)’s acquisition target Halucenex just picked up an extra 10g of ‘hard-to-access’ synthetic psilocybin - and now has 22.3g in total.

Creso Pharma (ASX: CPH) is listing on the US markets within weeks (via an OTC listing), but a similar company called MindMed is listing on the NASDAQ in 8 hours from now.

Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.

Creso Pharma (ASX:CPH) today announced its listing in the US, and the market is opening in around 12 hours - the US pool of investors is huge and they have a big appetite for psychedelics and cannabis stocks.

Creso Pharma Ltd (ASX:CPH | OTC:COPHF) has just confirmed two consecutive quarters of record revenue growth. CPH posted $1.71M revenue this quarter - up from $1.38M in the previous quarter - that’s 24% growth.

Today Creso Pharma’s (ASX:CPH) announced the acquisition of a range of CBD brand and product assets that deliver anti-inflammatory relief to professional and amateur athletes suffering from chronic muscle and joint pain.

The submission of the CTA is an important step in allowing Halucenex to prepare its planned phase II clinical trial to test the efficacy of psilocybin on treatment-resistant Post Traumatic Stress Disorder (PTSD).

Creso Pharma (CPH) strengthens its board with the appointment of William Lay as CEO and Managing Director Additionally, Bruce Linton has been appointed as Non-Executive Director and Micheline McKay has been appointed as Executive Director...

ASX health stocks (XHJ index) are up 0.75% today, compared to the ASX 200 which is up by 0.20%. Medicinal cannabis company, Bod Australia (ASX:BOD), has received a nod from the UK regulator to start an open label clinical trial for MediCabi...

Three new appointees with impressive sector experience are set to consolidate the company's push into North America.

 Creso Pharma has revealed its new CEO and broadened its team with two top industry leaders, strengthening the company’s 2022 foothold in North America.  This morning, Australian cannabis company, Creso Pharma (ASX:CPH)  announced the appoi...

Under siege Perth medicinal cannabis manufacturer Creso Pharma believes changes to laws are a strong revenue chance for its subsidiary company Halucenex.

“Post-approval, we anticipate a number of revenue-generating opportunities to materialise as Halucenex progresses its transition to a leading drug development and supply company," says Halucenex CEO.

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

Shares in the ASX cannabis sector have had another difficult time in December, as most majors come in well behind the benchmark. Investors are still crowding out of positions in ASX cannabis stocks at a fairly sturdy pace since our last u...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The Australian medicinal cannabis market has seen strong growth in 2021, with revenue from product sales estimated at $230 million. And medical cannabis prescriptions are at an all-time high. The TGA said 13,666 Australian patients were app...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

“Operationally, we remain focused on refining our growing techniques to ensure that our cannabis products continue to improve and THC content increases,” Jack Yu said.

The Creso Pharma Ltd (ASX: CPH) share price is climbing today after its Canadian subsidiary announced it has secured approval to produce more psychedelic substances. At the time of writing, Creso Pharma shares are in the green, up 6.25% t...

Halucenex Life Sciences, a subsidiary of Creso Pharma (CPH), secures an amendment to its Controlled Drugs and Substances Dealer’s Licence Granted by Health Canada, the amendment allows the company to produce, package and assemble psychedel...

“To be awarded the final components of our Dealer’s Licence from Health Canada is a major achievement for Halucenex. It follows extensive reviews of documentation and site security from the regulator, illustrating the high standard of our o...

Perth-based medicinal cannabis company Creso Pharma has entered a trading halt. It comes days after the business revealed it had been served with a notice by the corporate regulator. 

The All Ordinaries Index (ASX: XAO) enjoyed a very pleasing day of gains on Tuesday. The All Ords finished the day up 0.33% at 7,587.4 points. But one ASX share wasn’t even trading today. That would be the Creso Pharma Ltd (ASX: CPH) share...

The ASX returned to positive territory today as investors began to shrug off fears of the omicron variant, but the bourse is still well below levels seen last week. While utilities lost over 1%, most other sectors gained with telcos being t...

In late afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the day with a small gain. The benchmark index is currently up 0.1% to 7,405.1 points. Four ASX shares that have failed to follow the market higher today are...

The chairman of one of Australia’s top cannabis companies has stepped down today after it was revealed the corporate watchdog was looking into “suspected contraventions” by Creso Pharma (ASX: CPH), likely connected to an investigation into...

Shares in Creso Pharma Ltd (ASX: CPH) continue to take a battering today. At the time of writing, shares in the cannabinoid company are down 7% at 9.3 cents, having come off a 3-month high of 15 cents just 2 weeks earlier. Investors are p...

Adam Blumenthal will stand aside as chairman of Creso Pharma (CPH) to distance the company and its operations from an ongoing ASIC investigation CPH says it appears to have become involved in the probe due to common directorships with its...

Adam Blumenthal will stand aside as chairman of Perth-based Creso Pharma after it was revealed the cannabis products developer had become embroiled in an investigation launched by the corporate regulator.

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Uber is expanding its horizons, with plans to allow users to order cannabis on its Uber Eats app. Next week the app will list cannabis retailer Tokyo Smoke on its marketplace and customers will be able to place orders on the app – but they...

The Australian bourse recouped most of yesterday’s losses despite tech stocks dropping again, this time by 3.49%. The ASX 200 rose 0.78%, closing at 7,411 points, with the gains driven by the resources and energy sectors, which gained 2.3%...

The Creso Pharma [ASX:CPH] share price is falling as ASIC probes EverBlu Capital, whose executive chairman also serves as CPH’s non-executive chair and co-founder.   The post Why is the Creso Share Price Falling? (ASX:CPH) appeared first on...

Shares in medicinal cannabis company Creso Pharma Ltd (ASX: CPH) are sliding deep into the red during morning trade on Wednesday, down 6.12% to 11.5 cents. Investors were quick to dump their Creso holdings yesterday amid reporting from th...

The Magnis Energy Technologies Ltd (ASX: MNS) share price is motionless this morning. Shares in the lithium-ion battery manufacturer have entered a trading halt following reports of the company’s chair, Frank Poullas, being under investig...

The S&P/ASX 200 (ASX: XJO) fell another 0.7% on Tuesday despite strong comments from the Reserve Bank of Australia Governor who confirmed interest rates would be going nowhere until at least 2024. Every sector finished lower barring tec...